Weekly Sepsis Research Analysis
This week’s sepsis literature highlights mechanistic discoveries, device-focused prevention strategies, and novel prognostic biomarkers. A high-quality mechanistic study identifies lactate-driven HADHA lactylation (regulated by SIRT1/3) as a causal driver of septic myocardial depression. Translational device work shows an in situ nano‑selenium hydrogel coating reprograms macrophages and suppresses catheter thrombosis under septic conditions. A multicenter prospective cohort introduces an extrace
Summary
This week’s sepsis literature highlights mechanistic discoveries, device-focused prevention strategies, and novel prognostic biomarkers. A high-quality mechanistic study identifies lactate-driven HADHA lactylation (regulated by SIRT1/3) as a causal driver of septic myocardial depression. Translational device work shows an in situ nano‑selenium hydrogel coating reprograms macrophages and suppresses catheter thrombosis under septic conditions. A multicenter prospective cohort introduces an extracellular vesicle coagulolytic balance (EV‑CLB) that independently predicts 90‑day mortality in septic shock and may enable phenotype-guided anticoagulation strategies.
Selected Articles
1. Lactylation of HADHA Promotes Sepsis-Induced Myocardial Depression.
This mechanistic study maps extensive lysine lactylation in septic myocardium and identifies lactylation at HADHA K166 and K728 as functionally inhibiting HADHA activity, impairing mitochondrial function, reducing ATP production, and decreasing cardiomyocyte contractility. SIRT1 and SIRT3 regulate these modifications, and site-directed mutagenesis confirmed causal effects in LPS/CLP models and cell systems.
Impact: Provides a clear, intervention‑tractable mechanistic axis (HADHA lactylation / SIRT1/3) that links lactate signaling to septic cardiomyopathy and reframes lactate as an active modifier rather than solely a biomarker.
Clinical Implications: Supports development of therapies targeting lactylation (e.g., SIRT1/3 modulators) or HADHA function to prevent/treat septic myocardial depression and motivates measurement of cardiac lactylation in translational studies.
Key Findings
- Mapped 1,127 lysine lactylation sites and identified 83 differentially lactylated sites in sepsis.
- HADHA K166 and K728 lactylation inhibited enzymatic activity, impaired mitochondrial function and ATP production, and reduced cardiomyocyte contractility.
- SIRT1 and SIRT3 regulate HADHA lactylation; site-directed mutagenesis established causal links in in vivo (LPS/CLP) and in vitro models.
2. In situ self-growth nano-selenium hydrogel coating alleviates surface thrombosis of blood-contacting devices by inactivating inflammatory cells.
The study presents an in situ self‑growing nano‑selenium hydrogel coating that reprograms macrophages (↓M1, ↑M2; +146% M2/M1 ratio), reduces TF release and thrombin production, and suppressed coagulation and catheter thrombosis in LPS-induced rabbit models, pig vascular models, and translational observations in septic patients.
Impact: Introduces a translational, mechanism‑based device coating that mitigates thrombosis under intense inflammatory/septic conditions, with convergent in vitro, small and large animal, and patient observations.
Clinical Implications: If safety and durability are confirmed, such coatings could reduce catheter‑related thrombosis and inflammation in ICU/sepsis patients, lowering device failure and thromboinflammatory complications; human trials must assess selenium exposure and infection risks.
Key Findings
- Nano‑selenium hydrogel shifted macrophage polarization toward M2 (M2/M1 ratio +146%) and decreased proinflammatory cytokines.
- Coating reduced macrophage TF release and thrombin generation, suppressing coagulation in LPS rabbit models and in septic patients.
- Coated central venous catheters reduced thrombosis and vascular inflammatory activation in rabbit and pig vascular models.
3. The Procoagulant and Fibrinolytic Balance of Extracellular Vesicles Predicts Mortality in Septic Shock Patients.
In a multicenter prospective cohort of 225 septic shock patients, the EV‑CLB (ratio of TF‑dependent thrombin generation to uPA‑dependent plasmin generation) was significantly higher in non‑survivors at 24 h, independently predicted 90‑day mortality after adjustment, and correlated better with severity markers (SAPS II, lactate) than single EV procoagulant or fibrinolytic measures.
Impact: Presents a mechanistically anchored, externally relevant composite EV biomarker (EV‑CLB) that stratifies mortality risk in septic shock and could enable phenotype‑guided coagulation interventions.
Clinical Implications: EV‑CLB could be used for early prognostic stratification to identify patients for trials of anticoagulation or antifibrinolytic strategies; assay standardization and technical scalability are prerequisites for clinical adoption.
Key Findings
- EV‑CLB at 24 h was higher in non‑survivors versus survivors (median 2.78 vs 0.97 a.u.; p<0.001).
- Survivors demonstrated a decline in EV‑CLB from H0 to H48, a pattern not seen in non‑survivors.
- EV‑CLB independently predicted day‑90 mortality after multivariable adjustment and correlated strongly with SAPS II and lactate.